 Generic Zanaflex is an agonist at (alpha) 0-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, Generic Zanaflex has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of Generic Zanaflex are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.  The imidazoline chemical structure of Generic Zanaflex is related to that of the anti-hypertensive drug clonidine and other (alpha) 0 -adrenergic agonists. Pharmacological studies in animals show similarities between the two compounds, but Generic Zanaflex was found to have one-tenth to one-fiftieth (0/00) of the potency of clonidine in lowering blood pressure.  